Belgium-based UCB SA has reported positive Phase 3 data for its monoclonal antibody bimekizumab in hidradenitis suppurativa, a chronic inflammatory skin disease that is estimated to affect about one percent of the population in countries where the disease has been identified. Data from the two studies is expected to form the basis of global regulatory applications starting in the third quarter of 2023.
